✦ LIBER ✦

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: An EORTC gynecological cancer cooperative group study

✍ Scribed by J.V.Th.H. Hamerlynck; A.P. Maskens; C. Mangioni; M.E.L. van der Burg; J.A.M.J. Wils; J.B. Vermorken; N. Rotmensz

Book ID: 119052450
Publisher: Elsevier Science
Year: 1985
Tongue: English
Weight: 243 KB
Volume: 22
Category: Article
ISSN: 0090-8258
DOI: 10.1016/0090-8258(85)90045-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of fotemustine in patient

Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group

✍ M.S Aapro; F.H van Wijk; M.E.L van der Burg; W ten Bokkel Huinink; I Vergote; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Phase II study of vindesine in dissemina

Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study

✍ J. B. VERMORKEN; F. LANDONI; S. PECORELLI; M. J. PICCART; M. E. L. VAN DER BURG; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

Phase II trial of vinorelbine in patient

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

✍ C. Lhommé; J.B. Vermorken; E. Mickiewicz; B. Chevalier; A. Alvarez; C. Mendiola; 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 97 KB

A phase II study of high-dose medroxypro

A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer

✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Quality control in multicentric clinical

Quality control in multicentric clinical trials. An experience of the EORTC Gynecological Cancer Cooperative Group

✍ G Favalli; J.B Vermorken; K Vantongelen; J Renard; A.T Van Oosterom; S Pecorelli 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 220 KB

Phase II study of medroxyprogesterone ac

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

✍ Charles W Whitney; Virginia L Brunetto; Richard J Zaino; Samuel S Lentz; Joel So 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 157 KB